PBMC phenotype Proposed function Fresh sample Cryopre-served with Gibco medium Cryopre-served with the custom medium Kruskall-Wallis Statistics CD34+CD133+VEGFR2- “Early EPC” 0.3 ± 0.07 0.3 ± 0.1 0.3 ± 0.2 P<0.96 CD34+CD133+VEGFR2+ “Early EPC” 0.2 ± 0.06 0.09 ± 0.05 0.00 ± 0.00 P<0.17 CD34+CD133-VEGFR2+ “Early EPC” 0.6 ± 0.1 0.5 ± 0.2 0.2 ± 0.02 P<0.21 CD146+CD34+VEGFR2- “Late EPC” 1.1 ± 0.2 1.4 ± 0.4 1.6 ± 0.6 P<0.67 CD146+CD34+VEGFR2+ “Late EPC” 0.6 ± 0.1 0.4 ± 0.2 0.3 ± 0.1 P<0.26 CD146+CD34-VEGFR2+ “EC” 0.8 ± 0.3 0.6 ± 0.1 0.2 ± 0.1 P<0.07

Table 2: Subsets of EPC and EC from viable PBMC isolated from human blood (n=8) (Mean ± SEM). Data are expressed as percent of subsets per number live PBMC from the fresh samples and after cryopreservation for 7 days at -80°C (Gibco and the custom freezing medium). NS using Kruskall-Wallis test.